TY - JOUR T1 - The Performance of Psoriatic Arthritis Screening Questionnaires in Patients with Psoriasis JF - The Journal of Rheumatology JO - J Rheumatol SP - 1643 LP - 1645 DO - 10.3899/jrheum.180939 VL - 46 IS - 12 AU - AMIR HADDAD AU - JOY FELD AU - DEVY ZISMAN Y1 - 2019/12/01 UR - http://www.jrheum.org/content/46/12/1643.abstract N2 - Several screening questionnaires have been developed to identify patients with psoriatic arthritis (PsA) in the psoriasis population in dermatology and general practice settings1,2,3,4,5. However, the diagnosis of PsA using these questionnaires is a topic for debate, partly because of disease heterogeneity, and the complications from inconsistent performance results6,7,8,9.We aimed to evaluate the performance of the Psoriatic Arthritis Screening and Evaluation tool (PASE)1,2, the Psoriasis Epidemiology Screening Tool (PEST)2, the Toronto Psoriatic Arthritis Screen 2 (ToPAS 2)3, and the Early Arthritis for Psoriatic Patients (EARP)4 questionnaires in diagnosing PsA and to test the performance of the CONTEST questionnaire5 compared to the other existing tools.Patients with psoriasis from the dermatology and combined rheumatology-dermatology clinics in one medical center completed the PASE, ToPAS 2, PEST, and EARP questionnaires in random sequence prior to rheumatologic evaluation. The PASE, ToPAS 2, PEST, and EARP questionnaires were translated from English to Hebrew by a professional translator after the appropriate institutions gave approval to use these questionnaires. … Address correspondence to Dr. A. Haddad, Rheumatology Unit, Carmel Medical Center, 7 Michal St., Haifa 34362, Israel. E-mail: haddadamir{at}yahoo.com. ER -